Oxycodon-Neuraxpharm retard UNO 10 mg Retardtabletten Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

oxycodon-neuraxpharm retard uno 10 mg retardtabletten

neuraxpharm switzerland ag - oxycodoni hydrochloridum - retardtabletten - oxycodoni hydrochloridum 10 mg corresp. oxycodonum 8.97 mg, sacchari sphaerae, hypromellosum, talcum, acidum hydrochloridum, ethylcellulosum, hydroxypropylcellulosum, propylenglycolum, carmellosum natricum, cellulosum microcristallinum, magnesii stearas, silica colloidalis anhydrica, Überzug: poly(alcohol vinylicus), talcum, e 171, macrogolum 3350, pro compresso obducto corresp. saccharum max. 4.6 mg et natrium max. 2.16 mg. - analgesico - synthetika

Oxycodon-Neuraxpharm retard UNO 20 mg Retardtabletten Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

oxycodon-neuraxpharm retard uno 20 mg retardtabletten

neuraxpharm switzerland ag - oxycodoni hydrochloridum - retardtabletten - oxycodoni hydrochloridum 20 mg corresp. oxycodonum 17.94 mg, sacchari sphaerae, hypromellosum, talcum, acidum hydrochloridum, ethylcellulosum, hydroxypropylcellulosum, propylenglycolum, carmellosum natricum, cellulosum microcristallinum, magnesii stearas, silica colloidalis anhydrica, Überzug: poly(alcohol vinylicus), talcum, e 171, macrogolum 3350, e 172 (flavum), pro compresso obducto corresp. saccharum max. 9.2 mg et natrium max. 4.32 mg. - analgesico - synthetika

Oxycodon-Neuraxpharm retard UNO 40 mg Retardtabletten Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

oxycodon-neuraxpharm retard uno 40 mg retardtabletten

neuraxpharm switzerland ag - oxycodoni hydrochloridum - retardtabletten - oxycodoni hydrochloridum 40 mg corresp. oxycodonum 35.87 mg, sacchari sphaerae, hypromellosum, talcum, acidum hydrochloridum, ethylcellulosum, hydroxypropylcellulosum, propylenglycolum, carmellosum natricum, cellulosum microcristallinum, magnesii stearas, silica colloidalis anhydrica, Überzug: poly(alcohol vinylicus), talcum, e 171, macrogolum 3350, e 172 (rubrum), pro compresso obducto corresp. saccharum max. 18.4 mg et natrium max. 8.64 mg. - analgesico - synthetika

Oxycodon-Neuraxpharm retard UNO 80 mg Retardtabletten Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

oxycodon-neuraxpharm retard uno 80 mg retardtabletten

neuraxpharm switzerland ag - oxycodoni hydrochloridum - retardtabletten - oxycodoni hydrochloridum 80 mg corresp. oxycodonum 71.75 mg, sacchari sphaerae, hypromellosum, talcum, acidum hydrochloridum, ethylcellulosum, hydroxypropylcellulosum, propylenglycolum, carmellosum natricum, cellulosum microcristallinum, magnesii stearas, silica colloidalis anhydrica, Überzug: poly(alcohol vinylicus), talcum, e 171, macrogolum 3350, pro compresso obducto corresp. saccharum max. 36.8 mg et natrium max. 17.28 mg. - analgesico - synthetika

Dimethyl fumarate Neuraxpharm Unione Europea - italiano - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimetilfumarato - sclerosi multipla recidivante-remittente - immunosoppressori - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

LEVETIRACETAM NEURAXPHARM Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

levetiracetam neuraxpharm

neuraxpharm italy s.p.a. - levetiracetam - levetiracetam

Buccolam Unione Europea - italiano - EMA (European Medicines Agency)

buccolam

neuraxpharm pharmaceuticals s.l. - midazolam - epilessia - psicolettici - trattamento di convulsioni prolungate, acute, convulsive in neonati, bambini piccoli, bambini e adolescenti (da tre mesi a meno di 18 anni). buccolam deve essere utilizzato solo da parte dei genitori / accompagnatori in cui il paziente è stato diagnosticato di avere l'epilessia. per bambini tra i tre e i sei mesi di età, il trattamento deve essere in un ambiente ospedaliero dove il monitoraggio è possibile e attrezzature per la rianimazione è disponibile.

Briumvi Unione Europea - italiano - EMA (European Medicines Agency)

briumvi

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressori - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

ANSIOLIN Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

ansiolin

neuraxpharm italy s.p.a. - diazepam - diazepam